Sterling R&D - From Small Molecule API Development to Manufacture
Home Sterling R&D: from drug discovery to manufacture

Sterling R&D: from drug discovery to manufacture

Mike Gibson, R&D Director, Sterling Pharma Solutions

June, 03, 2020

At Sterling we provide first-class development services using both our state-of-the-art equipment and our experts’ insight to meet customers’ API project requirements – from early phase development to commercialisation, we accelerate products to market.

Our small molecule API development facilities can support the development of even the most challenging molecules. Our team is continuously investigating new technologies to further streamline our R&D offering to customer across drug discovery, process development and qualification and validation and transfer.

In this video our R&D Director, Mike Gibson, gives an overview of our R&D and technology capabilities, including our hazard evaluation and process development expertise, as well as the new product introduction process at Sterling.

For more information, or to speak to a member of the Sterling team, please get in touch.